Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Aggrastat Generic Name & Formulations
Legal Class
Rx
General Description
Tirofiban (as HCl monohydrate) 50mcg/mL; per bag or vial; soln for IV infusion; 250mcg/mL; per vial; soln for IV bolus; preservative-free.
Pharmacological Class
Antiplatelet.
How Supplied
Premixed bag (250mL)—1; Premixed vial (100mL)—1; Premixed bolus vial (15mL)—1
Manufacturer
Aggrastat Indications
Indications
To reduce the rate of thrombotic cardiovascular events (combined endpoint of death, MI, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome.
Aggrastat Dosage and Administration
Adult
See full labeling. May give bolus dose via a syringe or IV pump. Administer 25mcg/kg intravenously within 5mins and then 0.15mcg/kg/min via IV infusion pump for up to 18hrs. Renal impairment (CrCl ≤60mL/min): 25mcg/kg intravenously within 5mins and then 0.075mcg/kg/min for up to 18hrs.
Children
Not established.
Aggrastat Contraindications
Contraindications
Within previous 30 days: active internal bleeding, history of bleeding diathesis, major surgery, or severe physical trauma. History of thrombocytopenia after previous tirofiban therapy.
Aggrastat Boxed Warnings
Not Applicable
Aggrastat Warnings/Precautions
Warnings/Precautions
Monitor platelet counts 6hrs after initiation and daily thereafter. If platelet decreases to <90,000/mm3, monitor to exclude pseudothrombocytopenia. Discontinue tirofiban (and heparin) if thrombocytopenia confirmed. Previous exposure to a GP IIb/IIIa blocker may increase risk of thrombocytopenia. Minimize other arterial and venous punctures, IM injections, catheter use, nasotracheal intubation to lower bleeding risk. Severe renal insufficiency. Hemodialysis. Pregnancy. Nursing mothers.
Aggrastat Pharmacokinetics
See Literature
Aggrastat Interactions
Interactions
Increased risk of bleeding with concomitant fibrinolytics, anticoagulants, antiplatelets.
Aggrastat Adverse Reactions
Adverse Reactions
Bleeding (may be fatal), pelvic pain, bradycardia, coronary artery dissection; thrombocytopenia, anaphylaxis.
Aggrastat Clinical Trials
See Literature
Aggrastat Note
Not Applicable
Aggrastat Patient Counseling
See Literature
